Flotation still on but problems mount for Sulzer Medica
This article was originally published in Clinica
Executive Summary
Shares in Sulzer Medica continue to slide after the company warned of higher numbers of revision surgeries on patients implanted with its hip and knee products. The company also said that it was likely that the related costs would exceed the limits of its insurance coverage, which "could negatively impact earnings". Analysts have estimated that final costs could be as high as SFr1 billion ($560 million).
You may also be interested in...
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.